Blue Earth Diagnostics Showcases POSLUMA® Presentations

Blue Earth Diagnostics, a subsidiary of Bracco, and a leader in PET radiopharmaceuticals, has announced that its collaborators will share their findings at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. This event will take place from June 8 to 11, 2024, in Toronto, Canada. Among the key topics are the radiopharmaceuticals POSLUMA® and Axumin®, which are used for imaging prostate cancer.

POSLUMA, previously known as 18F-rhPSMA-7.3, is approved for PET imaging of PSMA-positive lesions in men with prostate cancer, either with suspected metastasis or recurrence based on increased PSA levels. Axumin is similarly approved for PET imaging in men with suspected prostate cancer recurrence, also based on elevated PSA levels after previous treatment.

David E. Gauden, Chief Executive Officer of Blue Earth Diagnostics, expressed satisfaction that their collaborators will present significant findings about POSLUMA and Axumin. Research to be presented includes a study by Dr. Isabel Rauscher from the Technical University of Munich, comparing the PET imaging parameters of 18F-flotufolastat and 68Ga-PSMA-11 in primary prostate cancer. Another presentation by Dr. Ismaheel Lawal of Emory University will discuss the interim results of using PET imaging with and without the diuretic furosemide in patients with biochemical recurrence of prostate cancer. Additionally, Dr. Nadine Mallak from Oregon Health and Science University will present interim results on the use of Axumin in PSMA/PET-negative patients with biochemical recurrence.

Blue Earth Diagnostics has also provided the schedule for these presentations. On June 9, 2024, Dr. Lawal will present a poster on evaluating biochemical recurrence of prostate cancer using 18F-rhPSMA 7.3 PET/CT and the effect of forced diuresis with furosemide. Dr. Rauscher will present a poster on comparing qualitative and quantitative PET parameters in prostate cancer patients using 18F-flotufolastat and 68Ga-PSMA-11. Moreover, Dr. Rauscher will deliver an oral presentation on June 8, 2024, about PET-guided salvage radiotherapy in recurrent prostate cancer.

Blue Earth Diagnostics will also host a Satellite Symposium titled “Let’s Talk about POSLUMA®.” This session will highlight the latest advances in PSMA-PET imaging for prostate cancer. The symposium will feature speakers such as Sean Collins from Georgetown University Hospital and Elizabeth Hawk from the University of California San Diego, with moderation by Todd Cohen, VP of Medical Affairs at Blue Earth Diagnostics. The event is scheduled for June 9, 2024, from 11:15 AM to 12:15 PM ET at the Toronto Convention Center.

Blue Earth's booth at SNMMI will provide further information about their clinical research and the company’s Medical Affairs team will be on hand to answer questions. Detailed session information and scientific presentation listings are available through the SNMMI online program.

Blue Earth Diagnostics, established in 2014 and now an indirect subsidiary of Bracco Imaging S.p.A., focuses on developing innovative diagnostic solutions for patient care. The company has a successful track record in developing and commercializing PET radiopharmaceuticals, with a growing oncology portfolio that includes prostate cancer and neuro-oncology.

Bracco Imaging, headquartered in Milan, Italy, is a leading provider of diagnostic imaging solutions. The company's portfolio includes agents for various imaging modalities, including X-ray, MRI, CEUS, and Nuclear Medicine. Through the acquisition of Blue Earth Diagnostics in 2019, Bracco Imaging has expanded its oncology nuclear imaging solutions portfolio. In 2021, Bracco Imaging further advanced its capabilities by establishing Blue Earth Therapeutics to develop radiopharmaceutical therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!